Aberrant hippocampal Ca2+ microwaves following synapsin-dependent adeno-associated viral expression of Ca2+ indicators

  1. Nicola Masala
  2. Manuel Mittag
  3. Eleonora Ambrad Giovannetti
  4. Darik A O'Neil
  5. Fabian J Distler
  6. Peter Rupprecht
  7. Fritjof Helmchen
  8. Rafael Yuste
  9. Martin Fuhrmann
  10. Heinz Beck
  11. Michael Wenzel  Is a corresponding author
  12. Tony Kelly  Is a corresponding author
  1. University of Bonn, Faculty of Medicine, Institute for Experimental Epileptology and Cognition Research (IEECR), Germany
  2. University Hospital Bonn, Germany
  3. Department of Epileptology, University Hospital Bonn, Germany
  4. Neuroimmunology and Imaging Group, German Center for Neurodegenerative Diseases (DZNE), Germany
  5. NeuroTechnology Center, Columbia University, United States
  6. Brain Research Institute, University of Zurich, Switzerland
  7. Neuroscience Center Zurich, University of Zurich, Switzerland
  8. German Center for Neurodegenerative Diseases (DZNE), Germany

eLife assessment

This important study provides convincing evidence of artefactual calcium microwaves during calcium imaging of populations of neurons in the hippocampus using methods that are common in the field. The work raises awareness of these artefacts so that any research labs planning to do calcium imaging in the hippocampus can avoid them by using alternative strategies that the authors propose.

https://doi.org/10.7554/eLife.93804.3.sa0

Abstract

Genetically encoded calcium indicators (GECIs) such as GCaMP are invaluable tools in neuroscience to monitor neuronal activity using optical imaging. The viral transduction of GECIs is commonly used to target expression to specific brain regions, can be conveniently used with any mouse strain of interest without the need for prior crossing with a GECI mouse line, and avoids potential hazards due to the chronic expression of GECIs during development. A key requirement for monitoring neuronal activity with an indicator is that the indicator itself minimally affects activity. Here, using common adeno-associated viral (AAV) transduction procedures, we describe spatially confined aberrant Ca2+ microwaves slowly travelling through the hippocampus following expression of GCaMP6, GCaMP7, or R-CaMP1.07 driven by the synapsin promoter with AAV-dependent gene transfer in a titre-dependent fashion. Ca2+ microwaves developed in hippocampal CA1 and CA3, but not dentate gyrus nor neocortex, were typically first observed at 4 wk after viral transduction, and persisted up to at least 8 wk. The phenomenon was robust and observed across laboratories with various experimenters and setups. Our results indicate that aberrant hippocampal Ca2+ microwaves depend on the promoter and viral titre of the GECI, density of expression, as well as the targeted brain region. We used an alternative viral transduction method of GCaMP which avoids this artefact. The results show that commonly used Ca2+-indicator AAV transduction procedures can produce artefactual Ca2+ responses. Our aim is to raise awareness in the field of these artefactual transduction-induced Ca2+ microwaves, and we provide a potential solution.

Introduction

There has been an explosion in the use of imaging techniques to record neuronal activity over the past 30 y, starting with the introduction of organic calcium indicators to measure neuronal population activity (Yuste and Katz, 1991) and accelerated by rapid advances in the development of genetically encoded Ca2+ indicators (GECIs) (Miyawaki et al., 1997). Specific advantages of neuronal Ca2+ imaging with GECIs lie in the ability of chronic cellular scale recordings of sizeable, densely labelled neuronal or glial populations with subtype specificity, without having to perturb the cell membrane or add a synthetic chemical to the brain (Grienberger and Konnerth, 2012; Rose et al., 2014; Semyanov et al., 2020).

Commonly used GECIs such as the GCaMP family have been continually improved since their initial development (Nakai et al., 2001), offering high signal-to-noise ratio, sensitivity, and response kinetics such that they can detect single-action potentials in vivo. This allows the reporting of cellular activity as well as the activity of sub-compartments such as the dendritic arbour (Chen et al., 2013; Dana et al., 2019; Zhang et al., 2023). Typically, GCaMP is expressed using transgenic animals or adeno-associated viral (AAV) transduction techniques (Tian et al., 2012; also see Grødem et al., 2023). The use of transgenic animals has the advantage of not requiring AAV transduction, thus reducing surgery load for animals and likelihood of indicator overexpression. In contrast, AAV GECI transduction is straightforward (breeding/crossing not required), can be targeted to virtually any brain region, and typically offers enhanced fluorescence (due to higher expression levels). Furthermore, AAV transduction avoids potential hazards due to chronic GECI expression during development.

While offering unprecedented new insights into cellular-scale neuronal network dynamics, it has also been reported that GECI expression in neurons can result in unwanted side effects. Depending on the expression approach, neurons have shown reduced dendritic branching and impairment in cell health, leading to cytotoxicity and cell death (Gasterstädt et al., 2020; Resendez et al., 2016). Furthermore, increased Ca2+ buffering due to the addition of Ca2+ indicators has been associated with alterations in intracellular Ca2+ dynamics (Grienberger and Konnerth, 2012; McMahon and Jackson, 2018). In addition, chronic expression of GCaMP can lead to accumulation in the nucleus and changes in gene expression (Yang et al., 2018). Again, depending on the specific expression approach, GCaMP variant, and experimental time course, such changes may alter cellular physiology and excitability. For example, increased firing rates have been observed in hippocampal neurons expressing GCaMP5G from CaMKIIa-Cre; PC::G5-tdT mice, and epileptiform activity in neocortex in some GCaMP6-expressing transgenic mice (Gee et al., 2014; Steinmetz et al., 2017).

Here, we describe microscale Ca2+ waves that are highly confined in space and progress slowly through the hippocampus following local GCaMP or R-CaMP viral transduction. Such aberrant hippocampal waves were typically first observed 4 wk following injection of commercially available AAVs expressing GCaMP6, GCaMP7, or R-CaMP1.07 under the synapsin promoter. The phenomenon occurred upon GECI transduction in CA1 and CA3, but not in dentate gyrus (DG) nor neocortex, was robustly observed across laboratories with various experimenters and setups, and highlights the necessity of careful use of transduction methods and control measures. Reducing the transduction titre diminished the likelihood of aberrant hippocampal Ca2+ waves, and an alternative viral transduction method employing sparser and Cre-dependent GCaMP6s expression in principal cells avoided the aberrant Ca2+ waves. Furthermore, in three transgenic GCaMP mouse lines (thy1-GCaMP6s or 6f; Vglut1-IRES2-Cre-D × Ai162(TIT2L-GC6s-ICL-tTA2)), aberrant Ca2+ microwaves were never observed. The aim of this article is to raise awareness in the field of artefactual transduction-induced Ca2+ waves and encourage others to carefully evaluate their Ca2+ indicator expression approach before embarking on chronic in vivo calcium imaging of the hippocampus.

Results

Aberrant Ca2+ microwave progression through the hippocampus

Based on published protocols, we injected AAV1 particles (pAAV.Syn.GCaMP6s.WPRE.SV40, Addgene #100843, titre 1 × 10¹³ vg/ml) into the hippocampus (total injection volume: 500 nl undiluted [1:1] virus solution) of C57BL/6 wildtype animals (6 weeks old) and performed in vivo two-photon imaging to record cellular activity at 2, 4, and 6–8 wk post-injection (p.i.) (Figure 1a). Viral transduction resulted in GCaMP6s expression throughout the hippocampal CA1, CA3, and DG areas under the imaging window (Figure 1b). As expected, the expression was primarily restricted to the ipsilateral hippocampus, with some labelling of projection pathways also in the contralateral hippocampus. There was no evidence of gross transduction-related morphological changes to the hippocampus (see Figure 1b), with no changes in CA1 pyramidal cell layer thickness or CA1 thickness (pyramidal layer thickness: 49 ± 12.5 µm ipsilateral and 50.3 ± 11.1 µm contralateral, n = 4, Student’s t-test p=0.89; CA1 thickness: 553.3 ± 14 µm ipsilateral and 555.8 ± 62 µm contralateral, n = 4, Student’s t-test p=0.94; 48 ± 13 wk p.i. at the time of perfusion). At 4 wk after injection, a time point commonly used for imaging cellular activity, we observed distinctive aberrant microscale Ca2+ waves that travelled through CA1 recruiting neighbouring cells (Figure 1c and d, Video 1, n = 4 mice). Ca2+ microwaves were maintained up to 6–8 wk after AAV injections (Figure 1e, n = 4 mice). In wildtype mice, these Ca2+ microwaves were not observed at an earlier time point (2 wk p.i.; p<0.05 using Kruskal–Wallis H-test for comparison between the three time points).

Development of Ca2+ microwaves travelling through hippocampus following GCaMP transduction.

(a) Experimental protocol to examine CA1 neuronal activity using two-photon imaging following adeno-associated viral (AAV) transduction of genetically encoded Ca2+ indicators. (b) Immunohistochemical sections following the last imaging session. GCaMP6s (AAV1.syn.GCaMP6s.SV40, Addgene #100843) expression throughout the ipsilateral hippocampus and projection pathways in the contralateral hippocampus. (c) Two-photon Ca2+ imaging of field of view (FOV) in CA1 at 4 wk post-injection (p.i.) showing aberrant Ca2+ microwaves (see also Video 1). Magnified inset shows three coloured neuronal subgroups (blue, orange, magenta) based on their spatial vicinity from a total population of 100 identified neurons (green). Right: time series of two-photon Ca2+ imaging FOVs showing two Ca2+ microwaves, the first at 0 s, the second appearing at 6 s (asterisk). The second wave progresses through FOV over dozens of seconds. (d) Raster plot of individual neuronal Ca2+ activity (ΔF/F, 1 min moving window, traces max-normalized per neuron) from neighbouring subgroups (colours correspond to c). Asterisk (same as in c): a Ca2+ microwave advances through neighbouring neuronal subgroups. (e) Occurrence rate (mean ± 95% CI) of aberrant Ca2+ microwaves with increasing expression time, following viral transduction of AAV1.syn.GCaMP6s.SV40 in mature C57BL/6 wildtype animals (n=4). n.d. = none detected. (f) Two-photon Ca2+ imaging FOV in the visual cortex at 6 wk p.i. (left) with normal sparse spontaneous Ca2+ activity and no detected Ca2+ microwaves (right; raster plot of ΔF/F, 1 min moving window, traces max-normalized per neuron).

Video 1
GCaMP6s two-photon calcium imaging in the hippocampal CA1 region, around 100 µm beneath the hippocampal surface (stratum pyramidale), FOV ~600x600 µm, ~4 wk after transduction of AAV1 particles containing pAAV.Syn.GCaMP6s.WPRE.SV40 (Addgene plasmid #100843) in a mature bl6 wildtype mouse.

Imaging wavelength = 940 nm, acquisition speed = 15 frames/s. Movie played at ×5 acquisition speed. Imaging was performed at the IEECR/University of Bonn.

The properties of the Ca2+ microwaves depended on the hippocampal region and exact recording location. For instance, although the Ca2+ waves were consistently observed in CA1, the spatial dimensions of the Ca2+ microwaves were broader in the stratum oriens compared with stratum pyramidale of CA1 (Videos 2 [str. pyr.] and Video 3 [str. oriens]), which likely reflects concomitant neuropil activation. We next examined whether the CA1 network is particularly prone to the generation of such waves and whether they show regional specificity. Upon viral GCaMP6s transduction under synapsin, Ca2+ waves were observed in both CA1 (n = 4/4; Videos 15) and CA3 (n = 1/1; Video 6), but interestingly, not in the DG (n = 3 mice, 4, 8, and 10 wk p.i., 40 min total recording time per mouse). In contrast to hippocampus, synapsin-dependent GCaMP6s expression restricted to the neocortex (V1 or somatosensory cortices) did not result in cortical Ca2+ waves in our hands (Figure 1f, n > 20 mice).

Video 2
GCaMP6s two-photon calcium imaging in the hippocampal CA1 region, around 100 µm beneath the hippocampal surface (stratum pyramidale), FOV ~450x450 µm, ~7 wk after transduction of AAV1 particles containing pAAV.Syn.GCaMP6s.WPRE.SV40 (Addgene plasmid #100843) in an ~3-month-old transgenic mouse (same as in Video 2; Scn2aA263V model of genetic epilepsy).

Imaging wave length = 940 nm, acquisition speed = 15 frames/s. Movie played at ×5 acquisition speed. Imaging was performed at the IEECR/University of Bonn.

Video 3
Same animal (Scn2aA263V model of genetic epilepsy) and time point of imaging as in Video 4.

GCaMP6s two-photon calcium imaging in the hippocampal CA1 region, around 25 µm beneath the hippocampal surface (stratum oriens), FOV ~350x350 µm, ~7 wk after transduction of AAV1 particles containing pAAV.Syn.GCaMP6s.WPRE.SV40 (Addgene plasmid #100843). Imaging wavelength = 940 nm, acquisition speed = 15 frames/s. Movie played at ×5 acquisition speed. Imaging was performed at the IEECR/University of Bonn.

Video 4
GCaMP6s two-photon calcium imaging in the hippocampal CA1 region, around 100 µm beneath the hippocampal surface (stratum pyramidale), FOV ~450x450 µm, ~2 wk after transduction of AAV1 particles containing pAAV.Syn.GCaMP6s.WPRE.SV40 (Addgene plasmid #100843) in an ~2-month-old transgenic mouse model of genetic epilepsy (heterozygous Scn2aA263V mouse).

Imaging wavelength = 940 nm, acquisition speed = 15 frames/s. Movie played at ×5 acquisition speed. Imaging was performed at the IEECR/University of Bonn.

Video 5
R-CaMP1.07 two-photon calcium imaging in the hippocampal CA1 region, around 100 µm beneath the hippocampal surface (stratum pyramidale), FOV ~200x200 µm, ~10 wk after transduction of AAV1 particles containing ssAAV-9/2-hSyn1-chI-RCaMP1.07-WPRE-SV40p(A) (Viral Vector Core UZH #V224-9) in a mature (~5 mo) bl6 wildtype mouse.

Imaging wavelength = 960 nm, acquisition speed = 30.88 frames/s. Movie played at ×5 acquisition speed. Imaging was performed at the Neuroscience Center Zurich (UZH).

Video 6
GCaMP6s two-photon calcium imaging in the hippocampal CA3 region, stratum pyramidale, FOV ~600x600 µm, ~7 wk after transduction of AAV1 particles containing pAAV.Syn.GCaMP6s.WPRE.SV40 (Addgene plasmid #100843) in a mature bl6 wildtype mouse.

Imaging wavelength = 940 nm, acquisition speed = 30.206 frames/s. Movie played at ×5 acquisition speed. Imaging was performed at Columbia University.

Aberrant Ca2+ microwaves in disease models

The observed Ca2+ microwaves were distinct from local seizure activity (no rhythmicity, no typical ictal evolution, no postictal depression) (Masala et al., 2023; Muldoon et al., 2015; Wenzel et al., 2017; Wenzel et al., 2019a) and spreading depolarization/depression phenomena (no concentric expansion, no post-wave neural depression). However, the occurrence of these artificial events may be confused as aberrant activity related to a pathology, especially when studying pathologies with known cellular and network hyperexcitability. For example, we initially found the aberrant hippocampal Ca2+ microwaves in the Scn2aA263V model of genetic epilepsy; however, these Ca2+ waves in CA1 of heterozygous animals (5/5 mice) were in general similar to those detected in wildtype animals at 4 wk p.i. In the Scn2aA263V model, in one case (1/5 animals), Ca2+ waves were observed even at 2 wk p.i. (Video 4). Furthermore, hippocampal transduction of jGCaMP7f under synapsin (Addgene #104488, AAV9 particles, original titre 2.5 × 10¹³ vg/ml, total injection volume 1000 nl [1:2 dilution]) in a mouse model of Alzheimer’s disease (PV-Cre::APPswe/PS1dE9) also resulted in Ca2+ microwaves (n = 3/6 mice). Together, these experiments show that common AAV injection procedures of GECIs under the synapsin promoter lead to artefactual hippocampal Ca2+ microwaves in wildtype mice and genetic mouse models of disease.

Properties and robustness of aberrant hippocampal Ca2+ waves

Next, we investigated the robustness of the aberrant Ca2+ microwaves across institutes and conditions. We chose to compare the incidence of aberrant Ca2+ microwaves in the CA1 region in four separate institutes in three different countries following transduction of GCaMP6s (Addgene #100843; IEECR/UoB, CU), GCaMP6m or jGCaMP7f (Addgene #100841 or #104488; DZNE), or RCaMP1.07 (Viral Vector Facility UZH #V224-9; UZH, Video 5; Table 1).

Table 1
Viruses used for the expression of genetically encoded calcium indicators (GECIs).

Viral titre is from Addgene documentation and was used at original concentration (dilution of 1:1) or at a dilution of 1:2. Syn.Flex.GCaMP6s and CamKII0.4.Cre were co-injected and therefore diluted to 1:2. Two-photon Ca2+ imaging was performed from 2 wk after injection in the hippocampus (CA1, CA3, or DG) or neocortex (Ctx). Ca2+ microwave incidence was determined from the number of animals exhibiting Ca2+ microwaves at the specified time point and region.

AAVConstructSource(Addgene id)Original titre(vg/ml)DilutionInjection volumePost-injection(wk)RegionCa2+-wave incidence (%)nMouse modelInstitute
AAV1Syn.GCaMP6s1008431 × 10131:10.52CA100/4wtUoB
AAV1Syn.GCaMP6s1008431 × 10131:10.54–6CA11004/4wtUoB
AAV1Syn.GCaMP6s1008431 × 10131:10.52CA1201/5Scn2a*UoB
AAV1Syn.GCaMP6s1008431 × 10131:10.54–8CA11005/5Scn2a*UoB
AAV1Syn.GCaMP6m1008411 × 10131:118CA1804/5wtDZNE
AAV1Syn.GCaMP6m1008411 × 10131:216CA1433/7wtDZNE
AAV1Syn.GCaMP6s1008431 × 10131:20.54–10DG00/3wtUoB
AAV9Syn.jGCaMP7f1044882.5 × 10131:2110–14CA1503/6APPsweDZNE
AAV1Syn.GCaMP6s1008431 × 10131:10.253–12CA3100 (1 exp.)1/1wtCU
AAV1Syn.GCaMP6s1008431 × 10131:10.253–5CA1100 (1 exp.)1/1wtCU
AAV1Syn.GCaMP6s1008431 × 10131:20.84–5Ctx00/>20
0/>20
wtCU
AAV1Syn.GCaMP6f1008377 × 10121:20.753–6Ctx0wtCU
AAV9hSyn1.R-CaMP1.07V224-9 4.3 × 10121:10.28CA11002/2wtUZH
AAV1syn.Flex.GCaMPm1008381 × 10131:20.534–38CA100/3wtDZNE
AAV9CamKII0.4.Cre.SV401055581 × 10131:2
AAV1syn.Flex.GCaMP6s1008451 × 10131:20.56CA100/2wtUoB
AAV1CamKII0.4.Cre.SV401055581 × 10131:2
  1. *

    In heterozygous Scn2aA263V mice.

  2. In PV-Cre::APPswe/PS1dE9 mice.

  3. Sourced from the Viral Vector Facility University of Zurich (VVF/UZH).

The incidence of aberrant hippocampal Ca2+ microwaves was robust, observed at the four different institutes each using variations of commonly used, published viral transduction procedures and standard two-photon Ca2+ imaging protocols (Table 1; see ‘Materials and methods’ for more details). Importantly, aside from the targeted region, the viral titre was important as halving the original AAV1.syn.GCaMP6m viral titre decreased the number of animals that developed aberrant Ca2+ microwaves from 80% of animals (4/5, original titre, 1 × 10¹³ vg/ml) to 43% of animals (3/7, 50% reduced titre, 0.5 × 1013 vg/ml) (see Table 1). To statistically test the involvement of expression level, we used a generalized linear model. For injections into CA1 in the hippocampus (n = 28), a multivariate logistic GLM (Ca2+ wave ~ dilution + p.i. wk) found both dilution and p.i. weeks were significantly related to Ca2+ wave incidence (model deviation above null = 7.5; dilution: z score = 2.18, p<0.05; p.i. wk: z score = 2.22, p<0.05).

To examine how robust the Ca2+ microwaves properties were, we compared properties across the different laboratories following expression of GCaMP6m and GCaMP6s variants. The occurrence rate of the aberrant Ca2+ microwaves was similar across the different institutes (Figure 2a). Ca2+ microwaves were spatially confined (diameter range of 200–300 µm), moved across the field of view (FOV) with slow progression speeds (speed range of 5–25 µm/s) (Figure 2b), and displayed no rhythmicity but rather plateau-like Ca2+ activity. No statistical differences were observed in Ca2+ microwave properties between the different institutes, suggesting that these values provide a reasonable range. In addition, the Ca2+ microwaves were not restricted to a single GECI variant or version, with Ca2+ waves observed following expression of GCaMP6m (n = 4), GCaMP6s (n = 5), and GCaMP7f (n = 3), as well as R-CaMP1.07 (n = 1) (Figure 2c and Table 1).

Aberrant Ca2+ microwaves are consistent across laboratories and genetically encoded calcium indicator (GECI) variant.

(a) Boxplot (median ± quartiles and range) of the occurrence rate of aberrant Ca2+ microwaves in CA1 at the different institutes at 6–8 wk after injection of GCaMP6s or GCaMP6m (number of animals in parenthesis). (b) Boxplots (median ± quartiles and range) of Ca2+ microwave diameters (left) and progression speed (right) in CA1 from each animal recorded across institutes. Inset: histogram of fluorescent intensity taken across each Ca2+-wave within an animal. Green line is the average, areas outside dashed lines mark 10% lowest fluorescence values, which were excluded from analysis. (c) Boxlot (median ± quartiles and range) of the occurrence rate of aberrant Ca2+ microwaves in CA1 following injection with commonly used GECIs (number of animals in parenthesis; see Table 1). (d) Two-photon Ca2+ imaging field of view (FOV) (left) in hippocampal CA1 following dual injection approach for conditional GCaMP6s expression (6 wk post-injection [p.i.]) with normal sparse spontaneous Ca2+ activity and no detection of Ca2+ microwaves (right; raster plot of ΔF/F, 1 min moving window, traces max-normalized per neuron).

In summary, upon synapsin-promoter-dependent AAV Ca2+ indicator expression, depending on the time of expression and viral transduction titre, Ca2+ microwaves were specifically observed in the CA1 and CA3 subregions of the hippocampus. For CA1, the Ca2+ microwaves were observed across laboratories and countries and animal models using common transduction procedures (for an overview, see Table 1).

Alternative transduction method of GCaMP to avoid aberrant Ca2+ microwaves

In light of these results, we tested an alternative expression approach to avoid aberrant hippocampal Ca2+ microwaves. To this end, we selected an approach to both limit the expression to principal cells and label a sparse population of the principal cells using a dual AAV injection approach. Here, Cre-dependent expression of GCaMP6s or GCaMP6m was achieved in a sparse population of principal cells under the CaMKII promoter (AAV1.syn.Flex.GCaMP6s.WPRE.SV40, Addgene #100845, and AAV1.CamKII0.4.Cre.SV40, Addgene #105558; n = 2 or, AAV1.Syn.Flex.GCaMP6m.WPRE.SV40, Addgene #100838 and AAV9.CamKII0.4.Cre.SV40, Addgene #105558; n = 3; Figure 2d; see O’Hare et al., 2022; Jimenez et al., 2020; Sheffield and Dombeck, 2015), upon which no Ca2+ microwaves were observed (0/5 animals, Figure 2d). Furthermore, hippocampal Ca2+ microwaves were neither observed in transgenic thy1-GCaMP6s nor 6f mice (JAX strain 025776 or 024276; up to 3 mo of chronic imaging in n > 30 mature mice age > p60, cumulative imaging time >200 hr), nor in Vglut1-IRES2-Cre-D mice crossed with Ai162(TIT2L-GC6s-ICL-tTA2)-D mice (JAX strains 037512, 031562; up to 3 mo of chronic imaging in n = 5 mature mice > p60).

Discussion

Here we report titre- and expression-time-dependent aberrant hippocampal Ca2+ microwaves in CA1 and CA3 regions following viral expression of GCaMP or R-CaMP1.07 under the synapsin promoter. These aberrant Ca2+ microwaves robustly occurred and were observed in four different institutes each using a common viral transduction approach and standard two-photon Ca2+ imaging protocols.

Ca2+ microwaves were typically first detected at ~4 wk, rarely also at 2 wk, after injection. Thus, there may be a time window when Ca2+ activity could be recorded in the absence of this artefactual phenomenon. However, we would still hesitate to use this specific approach for hippocampal imaging experiments as, although unknown from our data, more subtle alterations may occur prior to visible onset of aberrant activity. Furthermore, at sites more distal to the injection site with lower expression levels, Ca2+ microwaves may not be observed; however, it may very well be that Ca2+ microwaves in regions with higher expression will affect fine-scaled neuronal population dynamics in primarily unaffected neighbouring regions.

The presence of Ca2+ microwaves was not restricted to a single GCaMP variant or version, and was observed using either GCaMP6m, GCaMP6s, or GCaMP7f. The phenomenon was also observed upon transduction of R-CaMP1.07, indicating that these aberrant hippocampal waves are not restricted to GCaMP indicators, but rather present a general phenomenon following Ca2+-indicator transduction. Notably, the viral transduction titre was a key factor as reducing the viral transduction titre from 1 × 1013 vc/ml (500 nl or 1000 nl of a 1:1 undiluted virus solution) to 5 × 1012 vc/ml (1000 nl 1:2 solution, single injection) decreased, albeit did not yet prevent, the occurrence of Ca2+ microwaves. In the literature, hippocampal GCaMP transduction procedures in mice typically include one to several separate nearby injections, with a total volume of transduced undiluted virus ranging from 60 nl to 500 nl (Cai et al., 2016; Jimenez et al., 2020; Keinath et al., 2022; Pettit et al., 2022; Radvansky et al., 2021; Skocek et al., 2018; Szabo et al., 2022; Weisenburger et al., 2019; Wirtshafter and Disterhoft, 2022; Zaremba et al., 2017). In other studies, syn-GCaMP virus was diluted prior to injection (up to 1:10) (Jimenez et al., 2020; Zong et al., 2022), resulting in varied transduction volumes up to 1500 nl. In our hands, a reduced viral titre of 5 × 1012 vc/ml in a 1000 nl injection volume still resulted in aberrant Ca2+ microwaves. Thus, viral transduction titres per volume well below this number and diluted transduction solutions are advisable for syn-GCaMP expression in the hippocampus if AAV syn-Ca2+-indicator transduction is desired for a planned in vivo hippocampal imaging experiment.

If possible, alternate viral GCaMP expression approaches should be chosen. As a possible alternative, similar to previous reports using dual AAV injections or AAV in Cre-driver mouse lines (Farrell et al., 2020; Grosmark et al., 2021; Mineur et al., 2022; Rolotti et al., 2022; Terada et al., 2022), we find that Cre-dependent AAV GCaMP expression (IEECR/UoB) in pyramidal neurons does not cause aberrant hippocampal Ca2+ microwaves. Moreover, we have not observed this aberrant phenomenon in transgenic thy1-GCaMP6s or 6f mice (JAX strain 025776 or 024276) (Masala et al., 2023; Rupprecht et al., 2023; Wenzel et al., 2019b), nor in Vglut1-IRES2-Cre-D × Ai162(TIT2L-GC6s-ICL-tTA2)-D mice (JAX strains 037512, 031562). It goes beyond the scope and available resources in our laboratories to further identify which viral GCaMP transduction approaches avoid the reported phenomenon. It seems likely that the underlying mechanisms for this artefact comprise transduction titre and time period of GCaMP or R-CaMP1.07 expression, region specificity, and density of expression. Importantly, although our data suggest some regions and AAV constructs seem more prone to generate artefactual Ca2+ waves under certain conditions, this does not mean that Ca2+ waves cannot be generated in other regions or with other constructs or promoters. It remains unclear whether the observed phenomenon is restricted to Ca2+ indicator viral expression in mice or whether it extends to different animal models as well. In this regard, a previous report did not observe Ca2+-waves in rats following synapsin-dependent GCaMP6m expression, although notably, imaging was performed under isoflurane anaesthesia (Sosulina et al., 2021). Furthermore, disentangling the exact cellular mechanisms of the phenomenon from technical aspects is difficult as, for example, the mere change in the transduction procedure will affect GECI expression level. For instance, although Ca2+ waves were not observed following conditional expression of GCaMP with CaMKII.Cre, which may suggest a requirement for interneuronal expression, it may also simply reflect differences in final GCaMP expression density and levels between the two transduction procedures.

In the context of this study, the phenomenon of Ca2+ microwaves is possibly related to the expression of exogenous Ca2+ buffer and the resulting effects on Ca2+ dynamics and gene expression (McMahon and Jackson, 2018; Rose et al., 2014; Yang et al., 2018), which may be why our findings extended across genetically encoded Ca2+ indicators. Beyond clearly being abnormal, the exact nature of the observed Ca2+ microwaves remains unclear and may reflect Ca2+ influx during action potential firing or possibly Ca2+ release from internal stores. In a limited dataset, we tried to detect the Ca2+ microwaves by hippocampal LFP recordings (insulated tungsten wire, diameter ~110 µm). We could not identify a specific signature, for example, ictal activity or LFP depression, which may correspond to these Ca2+ microwaves. The shortcoming of these LFP recordings is that we could not simultaneously perform hippocampal two-photon microscopy, and thus, it is uncertain whether the Ca2+ microwaves indeed occurred in proximity to our electrode. We did not evaluate the effect of Ca2+ microwaves on physiological activity. Based on the data presented here, it appears reasonable to hypothesize that such waves obscure if not interfere with physiological activity, for example, with hippocampal place cell activity. However, the primary purpose of this article was to inform the community about an artefact that can be avoided using alternative approaches.

In summary, this report shows that common AAV hippocampal injection procedures of Ca2+ indicators may lead to aberrant Ca2+ microwaves in wildtype mice and genetic mouse models of disease, particularly if high-titre virus loads are used. The aim of this article is not to discredit Ca2+ indicators expressed under the synapsin promoter, a tool that we greatly appreciate ourselves, but to sensitize the field to artefactual transduction-induced aberrant Ca2+ microwaves. The underlying mechanisms, some of which we have described above, are likely multifaceted. This article seeks to inform and alert others to carefully evaluate their Ca2+ indicator expression approach for in vivo Ca2+ imaging of the hippocampus, which is becoming increasingly popular. There is certainly a much greater number of safe alternate hippocampal Ca2+ indicator viral expression approaches than has been reported here, and we encourage others to report on viral Ca2+ indicator transduction safety profiles. Indeed, others have also encountered these artefactual events as recent social media posts attest (Application Specialist Team, 2023). With more indicators of brain cell activity becoming available (Ca2+ indicators and others including voltage indicators) as well as routes for viral delivery (Grødem et al., 2023), the open and timely reporting of transduction safety profiles will reduce unnecessary animal experiments and save laboratory resources and time in future investigations into hippocampal function in health and disease.

Materials and methods

Animals

All experiments followed the EU animal welfare law (University of Bonn [81-02.04.2019.A139, 81-02.04.2019.A288], DZNE [84-02.04.2013.A356, 81-02.04.2018.A063]) or institutional guidelines of the Animal Care and Use Committee and respective federal office (Columbia University [AC-AAAV3464, AC-AAAM8851, AC-AAAH1804], University of Zurich [ZH211/2018]). We used wildtype C57BL/6J mice, Thy1-GCaMP6 mice (C57BL/6J-Tg(Thy1-GCaMP6s)GP4.12Dkim/J; Jackson Lab stock no. 025776, or C57BL/6J-Tg(Thy1-GCaMP6f)GP5.5Dkim/J; Jackson Lab stock Nno. 024276 [Dana et al., 2019]), Vglut1-IRES2-Cre-D mice (Jackson Lab stock no. 037512) crossed with Ai162(TIT2L-GC6s-ICL-tTA2)-D mice (Jackson Lab stock no. 031562), PV-Cre::APPswe/PS1dE9 (cross between B6;129P2-Pvalbtm1(cre)Arbr/J, Jackson Lab stock no. 008069, and B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, Jackson Lab stock no. 034832) or Scn2aA263V mice (from Schattling et al., 2016). Mice were kept under a light schedule of 12 hr on/12 hr off, constant temperature of 22 ± 2°C, and humidity of 65%. They had ad libitum access to water and standard laboratory food at all times. All efforts were made to minimize animal suffering and reduce the number of animals used.

Virus injections

For in vivo two-photon imaging experiments, GECIs were virally transduced using injection of an AAV (see Tables 1 and 2). At the time of injection, mice ranged in age from 5 to 79 wk. There was no significant relationship between the age of the animal and the incidence nor frequency of Ca2+ microwaves during this period (linear regression fit to the Ca2+ wave frequency against age was not significant: intercept = 1.37, slope = –0.007, p=0.62, n = 14; and generalized linear model relating Ca2+ wave incidence ~ age was not significant: z score = 0.19, deviance above null = 0.04, p=0.85, n = 24).

Table 2
Viral constructs used.
Resources table
Genetic reagent (Mus musculus)Recombinant DNA reagentAAVSourceID
Syn.GCaMP6sSyn.GCaMP6s.WPRE.SV40AAV1Addgene100843
Syn.GCaMP6mSyn.GCaMP6m.WPRE.SV40AAV1Addgene100841
Syn.jGCaMP7fSyn-jGCaMP7f-WPREAAV9Addgene104488
Syn.GCaMP6fSyn.GCaMP6f.WPRE.SV40AAV1Addgene100837
hSyn1.R-CaMP1.07hSyn1-chI-RCaMP1.07-WPRE-SV40p(A)AAV9VVF/UZHV224-9
syn.Flex.GCaMP6sSyn.Flex.GCaMP6s.WPRE.SV40AAV1Addgene100845
syn.Flex.GCaMP6mSyn.Flex.GCaMP6m.WPRE.SV40AAV1Addgene100838
CamKII0.4.Cre.SV40CamKII 0.4.Cre.SV40AAV1 or 9Addgene105558

At IEECR/University of Bonn

Request a detailed protocol

Mice (~6 wk of age) received ketoprofen (Gabrilen, Mibe; 5 mg/kg body weight [b.w.]; injection volume 0.1 ml/10 g b.w., subcutaneously [s.c.]) for analgesia and anti-inflammatory treatment 30 min prior to induction of anaesthesia. Then, mice were anaesthetized with 2–3% isoflurane in an oxygen/air mixture (25/75%) and then placed in a stereotactic frame. Eyes were covered with eye-ointment (Bepanthen, Bayer) to prevent drying, and body temperature was maintained at 37°C using a regulated heating plate (TCAT-2LV, Physitemp) and a rectal thermal probe. After hair removal and superficial disinfection, a drop of 10% lidocaine was used to locally anaesthetize the area. After 3–5 min, a flap of skin was removed about 1 cm² around the middle of the skull. Residual soft tissue was then removed from the skull with a scraper and 3% H2O2/NaCl solution. After complete drying, cranial sutures served as landmarks for the determination of injection sites. For virus injection, a burr hole was carefully drilled through the skull using a dental drill, avoiding excessive heating and injury to the meninges by intermittent cooling with sterile PBS. Coordinates were, for CA1, anterioposterior (AP) measured from bregma 1.9 mm, lateral (L) specified from midline 1.6 mm, dorsoventral (DV) from the surface of the skull 1.6 mm; for DG, AP 2.4 mm; L 1.6 mm; ×3 injections at DV 2.7, 2.5, and 2.1 mm. Virus particles (see Table 1) were slowly injected (20–100 nl/min). To prevent reflux of the injected fluid upon cannula retraction, it was left in place until 5 min post-injection and then carefully lifted.

At DZNE

Request a detailed protocol

A more detailed procedure was described previously (Fuhrmann et al., 2015; Poll et al., 2020). Briefly, mice (6–78 wk) were anaesthetized with i.p. injection of ketamine (0.13 mg/g) and xylazine (0.01 mg/g), head-fixed using a head holder (MA-6N, Narishige, Tokyo, Japan) and placed into a motorized stereotactic frame (Luigs-Neumann, Ratingen, Germany). Body temperature was constantly controlled by a self-regulating heating pad (Fine Science Tools, Heidelberg, Germany). After skin incision and removal of the pericranium, the position of the injection 34 G cannula was determined in relation to bregma. A 0.5 mm hole was drilled through the skull (Ideal Micro Drill, World Precision Instruments, Berlin, Germany). Stereotactic coordinates were taken from Franklin and Paxinos, 2008 (The Mouse Brain in Stereotaxic Coordinates, Third Edition, Academic Press). Virus (see Table 1) was injected in two loci with the following CA1 coordinates: AP 1.95 mm; L 1.5 mm; DV 1.15 mm at a speed of 100 nl/min.

At Columbia University

Request a detailed protocol

A more detailed procedure was described previously (Wenzel et al., 2017; Wenzel et al., 2019a). Briefly, mice (8–20 wk) were anaesthetized with isoflurane (initial dose 2–3% partial pressure in air, then reduction to 1–1.5%). For viral injections, a small cranial aperture was established using a dental drill above the somatosensory cortex (coordinates from bregma: AP 2.5 mm, L 0.24 mm, DV 0.2 mm), or V1 (coordinates from lambda: AP 2.5 mm, L 0.02 mm, DV 0.2–0.3 mm), or the hippocampus (coordinates from bregma, CA1: –1.9 mm, –1.6 mm, –1.6 mm; CA3: –2.2 mm, –2.3 mm, –2.7 mm). A glass capillary pulled to a sharp micropipette was advanced with the stereotaxic instrument, and virus particles (see Table 1) were injected into putative layer 2/3 of neocortex over a 5 min period at 50 nl/min, or hippocampus over 12.5 min using a UMP3 microsyringe pump (World Precision Instruments).

At University of Zurich

Request a detailed protocol

A more detailed procedure was described previously (Rupprecht et al., 2023). Briefly, mice (18 wk) were anaesthetized using isoflurane (5% in O2 for induction, 1–2% for maintenance during surgery) and provided with analgesia (Metacam 5 mg/kg b.w., s.c.). Body temperature was maintained at 35–37°C using a heating pad. An incision was made into the skin after local application of lidocaine. Viral particles (see Table 1) were injected into CA1 (coordinates AP –2.0 mm, ML –1.5 mm from bregma, DV –1.3) using a glass pipette with a manually driven syringe at a rate of approximately 50 nl/min. The injection pipette was left in place for further 5 min before being slowly retracted.

In vivo imaging window implantation procedure

Cranial window surgery was performed to allow imaging from the dorsal hippocampal CA1/CA3 region or neocortex.

At IEECR, University of Bonn

Request a detailed protocol

Thirty minutes prior to induction of anaesthesia, buprenorphine was administered for analgesia (Buprenovet, Bayer; 0.05 mg/kg b.w.; injection volume 0.1 ml/20 g b.w., intraperitoneally [i.p.]). Furthermore, dexamethasone (Dexa, Jenapharm; 0.1 mg/20 g b.w.; injection volume 0.1 ml/20 g b.w., i.p.), and ketoprofen (Gabrilen, Mibe; 5 mg/kg b.w.; injection volume 0.1 ml/10 g b.w., s.c.) were applied to counteract inflammation, swelling, and pain. Mice were anaesthetized with 2–3% isoflurane in an oxygen/air mixture (25/75%) and then placed in a stereotactic frame. Eyes were covered with eye-ointment (Bepanthen, Bayer), and body temperature was maintained at 37°C by closed-loop regulation through a warming pad (TCAT-2LV, Physitemp) and a rectal thermal probe. Throughout the course of the surgical procedure, the isoflurane dose was successively reduced to about 1–1.5% at a gas flow rate of ~0.5 ml/min. A circular craniotomy (Ø ~ 3 mm) was established above the right hemisphere/hippocampus within the central opening (Ø ~ 7 mm) of the head plate using a dental drill. Cortical tissue was carefully aspirated until the alveolar fibres above CA1 could be visually identified. A custom-made silicon cone (top Ø 3 mm, bottom Ø 2 mm, depth 1.5 mm, RTV 615, Momentive) attached to a cover glass (Ø 5 mm, thickness 0.17 mm) was inserted and fixed with dental cement around the edges of the cover glass (see Masala et al., 2023). Postoperatively, all mice received analgetic treatment by administration of buprenorphine twice daily (Buprenovet, Bayer; 0.05 mg/kg b.w.; injection volume 0.1 ml/20 g b.w., i.p.) and ketoprofen once daily (Gabrilen, Mibe; 5 mg/kg b.w.; injection volume 0.1 ml/10 g b.w., s.c.) for three consecutive days post-surgery. Throughout this time, animals were carefully monitored twice daily. Animals typically recovered from surgery within 24–48 hr, showing normal activity and no signs of pain or distress.

At DZNE

Request a detailed protocol

Prior to surgery, mice were anaesthetized with an intraperitoneal injection of ketamine/xylazine (0.13/0.01 mg per gram of body weight). Additionally, an anti-inflammatory (dexamethasone, 0.2 mg/kg) and an analgesic drug (buprenorphine hydrochloride, 0.05 mg/kg; Temgesic, Reckitt Benckiser Healthcare) were subcutaneously administered. A cranial window (Ø 3 mm) was implanted above the right hippocampus as previously described (Poll et al., 2020).

At Columbia University

Request a detailed protocol

For neocortical imaging, directly following virus injection, the craniotomy was covered with a thin glass cover slip (3 × 3 mm, No. 0, Warner Instruments), which was fixed in place with a slim meniscus of silicon around the edge of the glass cover and finally cemented on the skull using small amounts of dental cement around the edge. For hippocampal imaging, a small area of cortex (around 1.5 × 1.5 mm) above the left CA1 was removed by gentle suction down to the external capsule, as described previously (Dombeck et al., 2010; Wenzel et al., 2019b). The site was repeatedly rinsed with sterile saline until no further bleeding could be observed. Then, a small UV-sterilized miniature glass plug (1.5 × 1.5 mm, BK7 glass, obtained from BMV Optical), glued to the centre of a thin glass coverslip (3 × 3 mm, No. 0, Warner Instruments) with UV-sensitive glue, was carefully lowered onto the external capsule until the edges of the attached glass cover touched the skull surrounding the craniotomy. Finally, the plug was fixed in place with a slim meniscus of silicon around the edge of the glass cover and by applying small amounts of dental cement around the edge of the glass cover.

At University of Zurich

Request a detailed protocol

A more detailed procedure was described previously (Rupprecht et al., 2023). Briefly, 2 wk after virus injection, the hippocampal window was implanted. Two layers of light-curing adhesive (iBond Total Etch, Kulzer) were applied to the exposed skull, followed by a ring of dental cement (Charisma, Kulzer). A 3-mm-diameter ring was drilled into the skull, centred at the previous injection site. The cortex in the exposed region was carefully aspirated using a vacuum pump until the stripes of the corpus callosum became visible. The corpus callosum was left intact. A cylindrical metal cannula (diameter 3 mm, height 1.2–1.3 mm) attached with dental cement to a coverslip (diameter 3 mm) was carefully inserted into the cavity. The hippocampal window was fixed in place using UV-curable dental cement (Tetric EvoFlow, Ivoclar).

Two-photon Ca2+ imaging

A variety of standard commercially available two-photon systems were used at the different institutes to record the Ca2+ microwaves.

At IEECR, University of Bonn

Request a detailed protocol

A commercially available two-photon microscope was used (A1 MP, Nikon), equipped with a ×16 water-immersion objective (N.A. = 0.8, WD = 3 mm, CFI75 LWD 16X W, Nikon), and controlled using NIS-Elements software (Nikon). GCaMP6s was excited at 940 nm using a Ti:sapphire laser system (~60 fs laser pulse width; Chameleon Vision-S, Coherent). Emitted photons were collected using gated GaAsP photomultipliers (H11706-40, Hamamatsu). Several individual tif series were recorded by resonant scanning at a frame rate of 15 Hz for a total 20–40 min per imaging session.

At DZNE

Request a detailed protocol

Recordings of Ca2+-changes were performed with a galvo-resonant scanner (Thorlabs, Newton, USA) on a two-photon microscope equipped with a ×16 water immersion objective with a numerical aperture of 0.8 (N16XLWD-PF, Nikon, Düsseldorf, Germany) and a titanium sapphire (Ti:Sa) 80 MHz Cameleon Ultra II two-photon laser (Coherent, Dieburg, Germany) that was tuned to 920 nm for GCaMP6m fluorescence excitation. GCaMP6m fluorescence emission was detected using a band-pass filter (525/50 nm, AHF, Tübingen, Germany) and a GaAsP PMT (Thorlabs). ThorImageLS software (Thorlabs, version 2.1) was used to control image acquisition. Image series (896 × 480 pixels, 0.715 µm/pixel, or 640 × 256 pixels) were acquired at 30.3 Hz or 32.3 Hz.

At Columbia University

Request a detailed protocol

Neural population activity was recorded using a commercially available two-photon microscope (Bruker; Billerica, MA) and a Ti:sapphire laser (Chameleon Ultra II; Coherent) at 940 nm through a ×25 objective (Olympus, water immersion, N.A. 1.05). Resonant galvanometer scanning and image acquisition (frame rate 30.206 fps, 512 × 512 pixels) were controlled using Prairie View Imaging software.

At University of Zurich

Request a detailed protocol

Neuronal population activity was recorded using a custom-built two-photon microscope (see Rupprecht et al., 2023). Briefly light from a femtosecond-pulsed laser (MaiTai, Spectra Physics; tuned to 960 nm; power below objective 40–45 mW) was used to scan the sample below a ×16 objective (Nikon, water immersion, NA 0.8). Image acquisition and scanning (frame rate 30.88 Hz, 622 × 512 pixels) were controlled using custom-written software (Chen et al., 2013).

Analysis of aberrant Ca2+ microwaves

Request a detailed protocol

To remove motion artefacts, recorded movies were registered using a Lucas–Kanade model (Greenberg and Kerr, 2009) or the ImageJ plugin moco (available through the Yuste web page or https://github.com/NTCColumbia/moco, copy archived by NTCColumbia, 2016; Dubbs et al., 2016), or in the case of R-CaMP the NoRMCorre algorithm (Pnevmatikakis and Giovannucci, 2017).

We determined the diameter of the calcium waves in a semi-automated fashion from the raw tif series. Using ImageJ software, we first drew an orthogonal line across the largest aspect of each calcium wave progressing through the FOV, which resulted in a fluorescent histogram for each wave. Using custom code (MATLAB R2020b), we further analysed all histograms for each mouse and imaging time point. First, we applied a gentle smoothing, max-normalized each histogram, and max-aligned all histograms of a given imaging session. Then, after excluding the 10% lowest fluorescent values, the width of each calcium wave and a mean value were calculated for each time point/imaging session. Finally, the resulting pixel values were converted to micrometer, based on the respective objective (@ 512 × 512 pixels and ×1 zoom: Nikon ×16, NA 0.8, 3 mm WD: 1.579 µm/pixel; Olympus ×25, NA 1.05 2 mm WD: 0.92 µm/pixel). The speed of the Ca2+ microwaves was calculated from the duration and path length of the events visually identified and manually tracked in the FOV.

Histochemistry

Request a detailed protocol

To verify successful viral transduction and window position, animals were deeply anaesthetized with ketamine (80 mg/kg b.w.) and xylazine (15 mg/kg b.w.) at the end of the respective experiment. After confirming a sufficient depth of anaesthesia, mice were heart-perfused with cold phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS. Animals were decapitated and the brain removed and stored in 4% PFA in PBS solution for 24 hr. Then, 50–100-µm-thick coronal slices of the hippocampus were cut on a vibratome (Leica). For nuclear staining, brain slices were kept for 10 min in a 1:1000 DAPI solution at room temperature. Brain slices were mounted and the green and blue channel successively imaged under an epi-fluorescence or spinning disc microscope (Visitron VisiScope).

Data availability

Many example videos are included in the manuscript and supporting files. Raw data from a subset of animals are available at Zenodo (https://doi.org/10.5281/zenodo.12655766), due to size restrictions the full videos are available from the corresponding author upon request. Data and code required to reproduce the summary data figures is available at (https://github.com/tonykelly00/Ca_waves_data-Elife, copy archived at Kelly, 2024).

The following data sets were generated
    1. Kelly T
    (2024) Zenodo
    In-vivo two-photon imaging of aberrant Ca2+-waves following viral transduction of Ca2+ indicators in mice.
    https://doi.org/10.5281/zenodo.12655766

References

Article and author information

Author details

  1. Nicola Masala

    1. University of Bonn, Faculty of Medicine, Institute for Experimental Epileptology and Cognition Research (IEECR), Bonn, Germany
    2. University Hospital Bonn, Bonn, Germany
    3. Department of Epileptology, University Hospital Bonn, Bonn, Germany
    Present address
    Department of Anatomy and Neurobiology, University of California, Irvine, Irvine, United States
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared
  2. Manuel Mittag

    Neuroimmunology and Imaging Group, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared
  3. Eleonora Ambrad Giovannetti

    Neuroimmunology and Imaging Group, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared
  4. Darik A O'Neil

    NeuroTechnology Center, Columbia University, New York, United States
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared
  5. Fabian J Distler

    1. University of Bonn, Faculty of Medicine, Institute for Experimental Epileptology and Cognition Research (IEECR), Bonn, Germany
    2. University Hospital Bonn, Bonn, Germany
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared
  6. Peter Rupprecht

    1. Brain Research Institute, University of Zurich, Zurich, Switzerland
    2. Neuroscience Center Zurich, University of Zurich, Zurich, Switzerland
    Contribution
    Funding acquisition, Investigation, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8235-8257
  7. Fritjof Helmchen

    1. Brain Research Institute, University of Zurich, Zurich, Switzerland
    2. Neuroscience Center Zurich, University of Zurich, Zurich, Switzerland
    Contribution
    Resources, Supervision, Funding acquisition
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8867-9569
  8. Rafael Yuste

    NeuroTechnology Center, Columbia University, New York, United States
    Contribution
    Resources, Supervision, Funding acquisition
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4206-497X
  9. Martin Fuhrmann

    Neuroimmunology and Imaging Group, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
    Contribution
    Resources, Supervision, Funding acquisition
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7672-2913
  10. Heinz Beck

    1. University of Bonn, Faculty of Medicine, Institute for Experimental Epileptology and Cognition Research (IEECR), Bonn, Germany
    2. University Hospital Bonn, Bonn, Germany
    3. German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
    Contribution
    Resources, Supervision, Funding acquisition, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8961-998X
  11. Michael Wenzel

    1. University of Bonn, Faculty of Medicine, Institute for Experimental Epileptology and Cognition Research (IEECR), Bonn, Germany
    2. University Hospital Bonn, Bonn, Germany
    3. Department of Epileptology, University Hospital Bonn, Bonn, Germany
    Contribution
    Conceptualization, Formal analysis, Funding acquisition, Investigation, Writing – original draft, Writing – review and editing
    For correspondence
    michael.wenzel@ukbonn.de
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6065-1660
  12. Tony Kelly

    1. University of Bonn, Faculty of Medicine, Institute for Experimental Epileptology and Cognition Research (IEECR), Bonn, Germany
    2. University Hospital Bonn, Bonn, Germany
    Contribution
    Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing
    For correspondence
    tkelly@uni-bonn.de
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6066-0455

Funding

Deutsche Forschungsgemeinschaft (FOR-2715)

  • Heinz Beck
  • Tony Kelly

Deutsche Forschungsgemeinschaft (SPP2395)

  • Martin Fuhrmann
  • Heinz Beck

Deutsche Forschungsgemeinschaft (SFB1089)

  • Martin Fuhrmann
  • Heinz Beck
  • Michael Wenzel

Deutsche Forschungsgemeinschaft (BE 1822/13-1)

  • Heinz Beck

European Research Council

  • Fritjof Helmchen
  • Martin Fuhrmann
  • Michael Wenzel

National Science Foundation

  • Darik A O'Neil
  • Rafael Yuste

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank Lea Adenauer, Laura Kück, and Olga Zabashta for excellent technical support with animal husbandry and immunohistochemistry. We acknowledge the support of the Imaging Core Facility of the Bonn Technology Campus Life Sciences funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Projektnummer 388169927. The work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) with a Research Group FOR-2715 to TK and HB, SPP2395 to MF and HB, SFB1089 to MF, MW, and HB, and BE 1822/13-1 to HB. The work was further supported by the BONFOR Program UoB (MW: #2019-2-04), the Hertie Network of Excellence in Clinical Neuroscience (MW: #P1200008), European Research Council (MW: StG #101039945; FH: AdvG #670757, MF: CoG#865618), the Swiss National Science Foundation (project grant 310030B_170269 and Sinergia grant CRSII5 180316 to FH; Ambizione grant PZ00P3_209114 to PR). The work was further supported by the iBehave network (MF, HB, MW). Additional support was provided by the National Science Foundation (NSF GFRP to DAO; 2203119 to RY), National Institute of Neurological Disorders and Stroke (F99NS134209 to DAO and RM1NS132981 to RY), National Institute of Mental Health (R01MH115900 to RY), NSF (2203119 to RY), and a Vannevar Bush Faculty Fellowship (ONR N000142012828 to RY).

Ethics

All experiments followed the EU animal welfare law (University of Bonn [81-02.04.2019.A139, 81-02.04.2019.A288], DZNE [84-02.04.2013.A356, 81-02.04.2018.A063]) or institutional guidelines of the Animal Care and Use committee and respective Federal office (Columbia University [AC-AAAV3464, AC-AAAM8851, AC-AAAH1804], University of Zurich [ZH211/2018]).

Version history

  1. Sent for peer review:
  2. Preprint posted:
  3. Reviewed Preprint version 1:
  4. Reviewed Preprint version 2:
  5. Version of Record published:
  6. Version of Record updated:

Cite all versions

You can cite all versions using the DOI https://doi.org/10.7554/eLife.93804. This DOI represents all versions, and will always resolve to the latest one.

Copyright

© 2024, Masala et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,767
    views
  • 195
    downloads
  • 1
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Nicola Masala
  2. Manuel Mittag
  3. Eleonora Ambrad Giovannetti
  4. Darik A O'Neil
  5. Fabian J Distler
  6. Peter Rupprecht
  7. Fritjof Helmchen
  8. Rafael Yuste
  9. Martin Fuhrmann
  10. Heinz Beck
  11. Michael Wenzel
  12. Tony Kelly
(2024)
Aberrant hippocampal Ca2+ microwaves following synapsin-dependent adeno-associated viral expression of Ca2+ indicators
eLife 13:RP93804.
https://doi.org/10.7554/eLife.93804.3

Share this article

https://doi.org/10.7554/eLife.93804

Further reading

    1. Medicine
    2. Neuroscience
    LeYuan Gu, WeiHui Shao ... HongHai Zhang
    Research Article

    The advent of midazolam holds profound implications for modern clinical practice. The hypnotic and sedative effects of midazolam afford it broad clinical applicability. However, the specific mechanisms underlying the modulation of altered consciousness by midazolam remain elusive. Herein, using pharmacology, optogenetics, chemogenetics, fiber photometry, and gene knockdown, this in vivo research revealed the role of locus coeruleus (LC)-ventrolateral preoptic nucleus noradrenergic neural circuit in regulating midazolam-induced altered consciousness. This effect was mediated by α1 adrenergic receptors. Moreover, gamma-aminobutyric acid receptor type A (GABAA-R) represents a mechanistically crucial binding site in the LC for midazolam. These findings will provide novel insights into the neural circuit mechanisms underlying the recovery of consciousness after midazolam administration and will help guide the timing of clinical dosing and propose effective intervention targets for timely recovery from midazolam-induced loss of consciousness.

    1. Neuroscience
    John P Grogan, Matthias Raemaekers ... Sanjay G Manohar
    Research Article

    Motivation depends on dopamine, but might be modulated by acetylcholine which influences dopamine release in the striatum, and amplifies motivation in animal studies. A corresponding effect in humans would be important clinically, since anticholinergic drugs are frequently used in Parkinson’s disease, a condition that can also disrupt motivation. Reward and dopamine make us more ready to respond, as indexed by reaction times (RT), and move faster, sometimes termed vigour. These effects may be controlled by preparatory processes that can be tracked using electroencephalography (EEG). We measured vigour in a placebo-controlled, double-blinded study of trihexyphenidyl (THP), a muscarinic antagonist, with an incentivised eye movement task and EEG. Participants responded faster and with greater vigour when incentives were high, but THP blunted these motivational effects, suggesting that muscarinic receptors facilitate invigoration by reward. Preparatory EEG build-up (contingent negative variation [CNV]) was strengthened by high incentives and by muscarinic blockade, although THP reduced the incentive effect. The amplitude of preparatory activity predicted both vigour and RT, although over distinct scalp regions; frontal activity predicted vigour, whereas a larger, earlier, central component predicted RT. The incentivisation of RT was partly mediated by the CNV, though vigour was not. Moreover, the CNV mediated the drug’s effect on dampening incentives, suggesting that muscarinic receptors underlie the motivational influence on this preparatory activity. Taken together, these findings show that a muscarinic blocker impairs motivated action in healthy people, and that medial frontal preparatory neural activity mediates this for RT.